author-photo

Ann Kalita

Vanderbilt University Medical Center

18

Papers

1057

Citations

Citation Trend

Filter By

Papers (14) Sort By

Journal Conference Others

SAR and biological evaluation of analogues of a small molecule histone deacetylase inhibitor N-(2-aminophenyl)-4-((4-(pyridin-3-yl)pyrimidin-2-ylamino)methyl)benzamide (MGCD0103).

2009 Bioorganic & Medicinal Chemistry Letters
Show All
- Source
- Cite
- Save
Citations (8)
Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia.

2008 Blood
Show All
- Source
- Cite
- Save
Citations (229)
Design and synthesis of 4-[(s-triazin-2-ylamino)methyl]-N-(2-aminophenyl)-benzamides and their analogues as a novel class of histone deacetylase inhibitors

2008 Bioorganic & Medicinal Chemistry Letters
Show All
- Source
- Cite
- Save
Citations (29)
Phase I Study of MGCD0103 Given As a Three-Times-Per-Week Oral Dose in Patients With Advanced Solid Tumors

2008 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (110)
MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo

2008 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (262)
Evaluation of the Pharmacodynamic Effects of MGCD0103 from Preclinical Models to Human Using a Novel HDAC Enzyme Assay

2008 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (75)
4-(Heteroarylaminomethyl)-N-(2-aminophenyl)-benzamides and their analogs as a novel class of histone deacetylase inhibitors.

2008 Bioorganic & Medicinal Chemistry Letters
Show All
- Source
- Cite
- Save
Citations (13)
Discovery of N-(2-Aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an Orally Active Histone Deacetylase Inhibitor

2008 Journal of Medicinal Chemistry
Show All
- Source
- Cite
- Save
Citations (86)
Phase I/II: The oral isotype-selective HDAC inhibitor MGCD0103 in combination with gemcitabine in patients with refractory solid tumors

2007 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (0)
A phase I study of MGCD0103 given as a twice weekly oral dose in patients with advanced leukemias or myelodysplastic syndromes (MDS)

2007 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (12)